Skip to main content
    T

    Takeda Pharmaceutical Co Ltd ADR (TAK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $21.59
    +0.16 (+0.77%)

    Market Cap: $68.47B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Takeda Pharmaceutical Co Ltd ADR (TAK) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Takeda Pharmaceutical Co Ltd ADR (TAK) trades at 2.3x sales and 1.5x book value. Its P/S of 2.3x is above its 5-year median of 1.6x.

    Current Multiples

    TAK reports in JPY, so earnings multiples appear here only when its per-share earnings can be confirmed. Its free cash flow yield is 4.1%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales2.3x
    Price to book1.5x
    EV/EBITDA11.5x
    Price to FCF24.5x
    EV/FCF33.8x
    PEGN/A
    FCF yield4.1%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 35.3% above 1.7x and its P/B is 36.4% above 1.1x.

    MultipleCurrent5-year median10-year median
    P/S2.3x1.6x1.7x
    P/B1.5x1.0x1.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 1.4x in 2021 to 2.8x in 2017.

    Year endPriceP/SP/B
    2025$15.591.7x1.0x
    2024$13.241.4x0.9x
    2023$14.271.5x0.9x
    2022$15.601.6x1.0x
    2021$13.631.4x0.9x
    2020$18.201.9x1.3x
    2019$19.732.1x1.4x
    2018$16.821.6x1.4x
    2017$28.452.8x2.4x
    2016$20.782.7x1.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    P/E history is shown only for companies that report in US dollars.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About TAK

    Is TAK stock overvalued?

    GNG's valuation label for TAK is Overvalued.

    What is TAK's price to sales ratio?

    Takeda Pharmaceutical Co Ltd ADR has a price to sales ratio of 2.3x.